Cite
HARVARD Citation
D'Haens, G. et al. (n.d.). OP38 Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with moderately-to-severely active ulcerative colitis. Journal of Crohn's and colitis. pp. S026-S027. [Online].